Most cited papers from CSL (Switzerland)

CSL (Switzerland)

What are the most cited papers from CSL (Switzerland)?

The most cited paper from CSL (Switzerland) is "Part 8: Advanced Life Support" (Laurie J. Morrison et al., 2010), with 612 citations. Next come "Hemodynamic effects of exogenous and endogenous vasopressin at low plasma concentrations in conscious dogs." (272) and "Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease" (270).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 72 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Part 8: Advanced Life Support Laurie J. Morrison et al. · Circulation Open access125 authors	18 Oct 2010	612
2	Hemodynamic effects of exogenous and endogenous vasopressin at low plasma concentrations in conscious dogs. J-P Montani, J. F. Liard, Josiane Schoun et al. · Circulation Research Open access	Sep 1980	272
3	Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease Francesca Vinchi, Milene Costa da Silva, Giada Ingoglia et al. · Blood Open access	16 Dec 2015	270
4	Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor Hilary J Longhurst et al. · New England Journal of Medicine Open access	22 Mar 2017	238
5	Intravenous immunoglobulins – understanding properties and mechanisms Anne Durandy, Srini V. Kaveri, Taco Willem Kuijpers et al. · Clinical & Experimental Immunology Open access	30 Oct 2009	229
6	SIRT1 promotes lipid metabolism and mitochondrial biogenesis in adipocytes and coordinates adipogenesis by targeting key enzymatic pathways Yasser Majeed, Najeeb M. Halabi, Aisha Y. Madani et al. · Scientific Reports Open access	14 Apr 2021	219
7	Viral contamination in biologic manufacture and implications for emerging therapies Paul W. Barone et al. · Nature Biotechnology Open access	27 Apr 2020	215
8	Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE) Noel Gerard McElvaney et al. · The Lancet Respiratory Medicine Open access	Dec 2016	198
9	Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles Nicolas S. Merle et al. · JCI Insight Open access	20 Jun 2018	192
10	Pemphigus vulgaris identifies plakoglobin as key suppressor of c‐Myc in the skin Lina Williamson, Natalia Raess, Reto Caldelari et al. · The EMBO Journal Open access	26 Jul 2006	182
11	Transferrin receptor in human placental brush border membranes. Studies on the binding of transferrin to placental membrane vesicles and the identification of a placental brush border glycoprotein with high affinity for transferrin. Hiroshi Wada, P E Hass, Howard H. Sussman · Journal of Biological Chemistry Open access	Dec 1979	174
12	SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern Anupriya Aggarwal et al. · EBioMedicine Open access	17 Sep 2022	161
13	Next-generation Fc receptor–targeting biologics for autoimmune diseases Adrian W. Zuercher, Rolf Spirig, Adriana Baz Morelli et al. · Autoimmunity Reviews Open access	9 Aug 2019	157
14	Subcutaneous immunoglobulin: opportunities and outlook Siraj Misbah, Matthias Sturzenegger, Michael Borte et al. · Clinical & Experimental Immunology Open access	30 Oct 2009	145
15	Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia Francesco Cosentino, David Hürlimann, Chiara Gatti et al. · Heart Open access	4 Oct 2007	145
16	C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 study Timothy Craig, Againdra K. Bewtra, Sami L. Bahna et al. · Allergy Open access	2 Sep 2011	143
17	The ultrastructure of Ignicoccus: Evidence for a novel outer membrane and for intracellular vesicle budding in an archaeon Reinhard Rachel, Irith Wyschkony, Sabine Riehl et al. · Archaea Open access	13 Aug 2001	135
18	Therapeutic Effect of IVIG on Inflammatory Arthritis in Mice Is Dependent on the Fc Portion and Independent of Sialylation or Basophils Ian K. Campbell, Sylvia Miescher, Donald R. Branch et al. · The Journal of Immunology Open access	24 Apr 2014	133
19	Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency John B. Hagan, Mary Beth Fasano, Sheldon L. Spector et al. · Journal of Clinical Immunology Open access	7 May 2010	131
20	Immunologic and functional evidence for anti–Siglec-9 autoantibodies in intravenous immunoglobulin preparations Stephan von Gunten, Alexander Schaub, Monique Vogel et al. · Blood Open access	10 Aug 2006	130
21	Novel Formulation of a Reconstituted High-Density Lipoprotein (CSL112) Dramatically Enhances ABCA1-Dependent Cholesterol Efflux Svetlana Diditchenko, Andreas Gille, Ingo Pragst et al. · Arteriosclerosis Thrombosis and Vascular Biology	19 Jul 2013	127
22	Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency W. Kreuz, Esther Meili, Kristiina Peter-Salonen et al. · Transfusion and Apheresis Science	25 May 2005	127
23	Analysis and Functional Consequences of Increased Fab-Sialylation of Intravenous Immunoglobulin (IVIG) after Lectin Fractionation Fabian Käsermann, David J. Boerema, Rüegsegger Monika et al. · PLoS ONE Open access	4 Jun 2012	123
24	Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy Stephen R.A. Jolles, Ewa Anna Bernatowska, J. de Gracia et al. · Clinical Immunology Open access	25 Jun 2011	120
25	Efficacy and Safety of the Factor VIII/von Willebrand Factor Concentrate, Haemate-P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand Disease Man‐Chiu Poon, Irwin Walker, Fan Xie et al. · Thrombosis and Haemostasis	2002	120
26	Sialylation‐independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin Danila Leontyev, Yulia Katsman, Xue‐Zhong Ma et al. · Transfusion	18 Jan 2012	116
27	Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 induction John D. Belcher, Chunsheng Chen, Julia Nguyen et al. · PLoS ONE Open access	25 Apr 2018	114
28	Low pH-Dependent Endosomal Processing of the Incoming Parvovirus Minute Virus of Mice Virion Leads to Externalization of the VP1 N-Terminal Sequence (N-VP1), N-VP2 Cleavage, and Uncoating of the Full-Length Genome Bernhard Mani, Claudia Baltzer, Noelia Valle et al. · Journal of Virology Open access	26 Dec 2005	112
29	Factor XIII Substitution in Surgical Cancer Patients at High Risk for Intraoperative Bleeding Wolfgang C. Korte, Christine Szadkowski, Anita Gähler et al. · Anesthesiology	22 Jan 2009	110
30	Effects of alterations in cellular iron on biosynthesis of the transferrin receptor in K562 cells. K. K. Rao, Daniel S. Shapiro, Elena Di Mattia et al. · Molecular and Cellular Biology Open access	Apr 1985	109
31	Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data Albrecht Gröner, Ye Jian, Pendrak Inna et al. · Thrombosis and Haemostasis	11 Dec 2014	106
32	Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112 Svetlana A. Didichenko, Alexei V. Navdaev, Alexandre M.O. Cukier et al. · Circulation Research Open access	20 Jul 2016	105
33	Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies Herbert O. Dichtelmüller, Lothar BIESERT, Fabrizio Fabbrizzi et al. · Transfusion Open access	20 May 2009	105
34	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI Guillaume Marquis‐Gravel, Frederik Dalgaard, Aaron D. Jones et al. · Journal of the American College of Cardiology Open access	Jul 2020	104
35	Intravenous immunoglobulin preparations contain anti–Siglec-8 autoantibodies Stephan von Gunten, Monique Vogel, Alexander Schaub et al. · Journal of Allergy and Clinical Immunology	3 Mar 2007	104
36	Plasma vasopressin concentrations and effects of vasopressin antiserum on blood pressure in rats with malignant two-kidney Goldblatt hypertension. Jan Möhring, Bärbel Möhring, Maria Petri et al. · Circulation Research Open access	1978	103
37	Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema William R. Lumry, Timothy Craig, Bruce L. Zuraw et al. · The Journal of Allergy and Clinical Immunology In Practice Open access	31 Jan 2018	101
38	Pharmacokinetic analysis of plasma‐derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B Bruce M. Ewenstein, J. Heinrich Joist, Amy D. Shapiro et al. · Transfusion	Feb 2002	101
39	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks Timothy Craig et al. · The Journal of Allergy and Clinical Immunology In Practice Open access	14 Feb 2019	100
40	C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction Christoph Caliezi, Sacha Sergio Zeerleder, Maurice Redondo et al. · Critical Care Medicine	Aug 2002	100
41	DIFFERENTIAL IMMUNE RESPONSE TO INFLUENZA AND PNEUMOCOCCAL VACCINATION IN IMMUNOSUPPRESSED PATIENTS AFTER HEART TRANSPLANTATION Thomas J. Dengler, Nicola Strnad, Irina B hring et al. · Transplantation	Nov 1998	98
42	The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites Christoph Schneider, David F. Smith, Richard D. Cummings et al. · Science Translational Medicine Open access	7 Jan 2015	98
43	Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies Mark R. Stein, Robert P. Nelson, Joseph A. Church et al. · Journal of Clinical Immunology Open access	23 Sep 2008	96
44	Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass Stephan von Gunten, David F. Smith, Richard D. Cummings et al. · Journal of Allergy and Clinical Immunology Open access	14 May 2009	95
45	Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P) Gerhard Dickneite, Ingo Pragst, Christine Joch et al. · Blood Coagulation & Fibrinolysis	29 Sep 2009	93
46	Facial follicular porphyrin fluorescence: correlation with age and density of Propionibacterium acnes Kenneth J. McGinley, GUY F. WEBSTER, JAMES J. LEYDEN · British Journal of Dermatology	Apr 1980	92
47	Forty-two-years later: the outcome of childhood-onset schizophrenia Helmut Remschmidt, Miguel Ángel Martı́n, Christian Fleischhaker et al. · Journal of Neural Transmission	5 Aug 2006	88
48	Bioavailability of IgG Administered by the Subcutaneous Route Melvin Berger, Stephen R.A. Jolles, Jordan Scott Orange et al. · Journal of Clinical Immunology Open access	28 Feb 2013	88
49	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction Charles Michael Gibson et al. · American Heart Journal Open access	13 Oct 2020	85
50	The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease Rolf Spirig, Janice C S Tsui, Sidney Shaw · Cardiology Research and Practice Open access	2012	80

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.